|
|
|
| Current Status and Trend of R&D of Monoclonal Antibodies |
Qian GAO( ),Hong JIANG,Mao YE,Wen-juan GUO |
| Wuhan Library,Chinese Academy of Sciences,Wuhan 430071, China |
|
|
|
Abstract Monoclonal antibodies have played an inestimable role in the treatment of cancer and autoimmune diseases with their unique mechanism and high efficiency, which have become the focus of research in biopharmaceutics. In this paper, all the data was extracted from Clarivate via Cortellis. Through the combination of quantitative data analysis and expert wisdom, the competitive landscape of monoclonal antibodies was presented from various dimensions, including the overall trend of R&D and industrialization, focus countries, technology and drug categories, targets, market share and commercial deal. The results showed that among the 133 kinds of launched monoclonal antibodies recently, 37.6% of them belonged to humanized monoclonal antibodies. HER, TNF, CD20, PD-1/L1, VEGF and CD3 were the “hot” antibody target molecule, of the total number of target-based actions which was the most numerous in HER2 tyrosine kinase receptor inhibitor. The total volume of monoclonal antibodies in China ranked second to the United States. But there were only 8 monoclonal antibodies approved in China, which was far below the level of United States. There were 22 launched monoclonal antibodies achieved annual sales over $1 biliion in 2017. Access to 1408 monoclonal antibodies deal records, drug development/commercial license was the primary agreement type. In the future, the development trend of monoclonal antibodies will be focused on new targets, new indications and new therapeutic schemes, and then more “blockbuster drugs” will be produced.
|
|
Received: 18 September 2018
Published: 12 April 2019
|
|
|
|
Corresponding Authors:
Qian GAO
E-mail: gaoq@mail.whlib.ac.cn
|
|
|
| [1] |
任会琴, 张永莉, 吴剑涓 , 等. 单克隆抗体药物在抗血栓治疗中的应用及研究进展. 中国医院药学杂志, 2010,30(09):787-789.
|
|
|
| [1] |
Ren H Q, Zhang Y L, Wu J J . Application and research advance of monoclonal antibodies in antithrombotic therapy. Chinese Journal of Hospital Pharmacy, 2010,30(09):787-789.
|
|
|
| [2] |
Rodgers K R, Chou R C . Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions. Biotechnology Advances, 2016,34(6):1149-1158.
doi: 10.1016/j.biotechadv.2016.07.004
pmid: 27460206
|
|
|
| [3] |
Barbacci E G, Pustilnik L R, Rossi A M , et al. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Research, 2003,63(15):4450-4459.
doi: 10.1097/00002820-200308000-00012
pmid: 12907618
|
|
|
| [4] |
Choy E H, Panayi G S . Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine, 2001,344(12):907-916.
doi: 10.1056/NEJM200103223441207
|
|
|
| [5] |
Kempeni J . Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7. Annals of The Rheumatic Diseases, 1999,58(Suppl 1):170-172.
doi: 10.1136/ard.58.2008.i70
pmid: 1766582
|
|
|
| [6] |
Scallon B J, Moore M A, Trinh H , et al. Chimeric anti- TNF- alpha monoclonal antibody cA2 binds recombinant transmembrane TNF alpha and activates immune effector functions. Cytokine, 1995,7(3):251-259.
doi: 10.1006/cyto.1995.0029
|
|
|
| [7] |
Keating G M . Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 2010,70(11):1445-1476.
doi: 10.2165/11201110-000000000-00000
|
|
|
| [8] |
Abdel-Rahman O , ElHalawani H . Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. Expert Opinion on Drug Safety, 2014,13(11):1443-1467.
doi: 10.1517/14740338.2014.955848
pmid: 25244502
|
|
|
| [9] |
Wildiers H, Guetens G, De Boeck G , et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. British Journal of Cancer, 2003,88(12):1979-1986.
|
|
|
| [10] |
Robert C, Long G V, Brady B , et al. Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine, 2015,372(4):320-330.
doi: 10.1056/NEJMoa1412082
pmid: 25399552
|
|
|
| [11] |
Kimball A B, Gordon K B, Langley R G , et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial. Archives of Dermatology, 2008,144(2):200-207.
doi: 10.1001/archdermatol.2007.63
pmid: 18283176
|
|
|
| [12] |
Singh A S, Chawla N S, Chawla S P . Giant-cell tumor of bone: Treatment options and role of denosumab. Biologics:Targets &Therapy, 2015,9:69-74.
doi: 10.2147/BTT.S57359
pmid: 4507456
|
|
|
| [13] |
汤佳琳, 黄镜 . PD-1/PD-L1免疫检查点抑制剂在晚期结直肠癌的药物治疗进展. 癌症进展, 2017,15(8):872-875.
doi: 10.11877/j.issn.1672-1535.2017.15.08.06
|
|
|
| [13] |
Tang J L, Huang J . The treatment progress on PD-1/PD-L1 immune checkpoint inhibitor treating advanced colorectal cancer. Oncology Progress, 2017,15(8):872-875.
doi: 10.11877/j.issn.1672-1535.2017.15.08.06
|
|
|
| [14] |
Rosenfeld P J, Rich R M, Lalwani G A . Ranibizumab: Phase III clinical trial results. Ophthalmology Clinics of North America, 2006,19(3):361-372.
doi: 10.1016/j.ohc.2006.05.009
pmid: 16935211
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
